Event

Pulmonary hypertension (PH) currently has no cure, thus PH research remains a high priority for NHLBI. In 2014, NHLBI launched a major multi-center clinical study of PH named: Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS). This program includes one Data Coordinating Center (DCC) and six U.S. clinical centers that are conducting an observational study in patients with all types of PH. The overall goal of the PVDOMICS network is to perform comprehensive phenotyping across WHO groups as well as intermediate phenotypes in order to reconstruct the traditional classification and define new meaningful subclassifications. Currently, since the start of enrollment in 2017, there have been over 235 participants with a goal of 1500 by March 2019. This session will describe initial results from the study in approximately the first 700 subjects.